Skip to main content

Table 2 Effect of TSF and placebo on Scr, BUN, UAER, eGFR and ln plasma L-FABP levels in patients with microalbuminuria

From: Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Parameters Groups Baseline Week 12 Week 24
UAER (μg/min) TSF 157.6 ± 72.9 115.9 ± 50.7 104.0 ± 32.4a
Placebo 158.6 ± 99.0 116.5 ± 69.7 121.8 ± 69.7
BUN (mmol/L) TSF 5.1 ± 1.2 5.6 ± 1.4 5.5 ± 1.4
Placebo 5.7 ± 1.6 6.6 ± 1.5 6.0 ± 2.3
Scr (μmol/L) TSF 73.5 ± 19.3 64.4 ± 19.7 67.6 ± 16.7
Placebo 60.8 ± 18.2 62.7 ± 19.8 61.9 ± 15.1
eGFR (ml/min/1.73 m2) TSF 102.7 ± 39.2 118.3 ± 49.4 113.9 ± 53.5
Placebo 128.3 ± 61.0 124.8 ± 45.2 121.0 ± 44.0
ln plasma L-FABP (μg/ml) TSF 1.0 ± 0.9 1.3 ± 0.8 1.2 ± 0.7
Placebo 1.4 ± 0.7 1.7 ± 0.6 1.1 ± 0.7
  1. All values expressed as mean ± SD
  2. a: P < 0.05 compared with baseline of the same group (Paired t test)
  3. Abbreviations: BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, ln plasma L-FABP ln-transformed plasma liver-type fatty acid binding protein, Scr serum creatinine, UAER urinary albumin excretion rate